Gilead Sciences, Inc.
Toronto Stock ExchangeTotal Valuation
Gilead Sciences, Inc. carries a market capitalization of 251.60B, placing it among publicly traded companies globally. Its enterprise value stands at 45.37B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 251.60B |
| Enterprise Value | 45.37B |
Share Statistics
Gilead Sciences, Inc. currently has 1.24B shares outstanding.
| Shares Outstanding | 1.24B |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Gilead Sciences, Inc. trades at a trailing price-to-earnings ratio of 13.45. The price-to-sales ratio is 4.90, and the price-to-book ratio stands at 1.89.
| PE Ratio | 13.45 |
| PS Ratio | 4.90 |
| PB Ratio | 1.89 |
| P/TBV Ratio | -2.13 |
| P/FCF Ratio | 10.61 |
| P/OCF Ratio | 11.01 |
Enterprise Valuation
On an enterprise value basis, Gilead Sciences, Inc. trades at an EV/EBITDA multiple of 3.13 and an EV/FCF ratio of 2.87. The EV/Sales ratio of 1.49 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 3.87 provides insight into valuation relative to core operating earnings.
| EV / Sales | 1.49 |
| EV / EBITDA | 3.13 |
| EV / EBIT | 3.87 |
| EV / FCF | 2.87 |
Financial Position
Gilead Sciences, Inc. maintains a current ratio of 1.27, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 223.48, indicating elevated leverage, while an interest coverage ratio of 14.51 demonstrates strong ability to service its debt obligations.
| Current Ratio | 1.27 |
| Quick Ratio | 0.75 |
| Debt / Equity | 223.48 |
| Debt / EBITDA | 1.81 |
| Interest Coverage | 14.51 |
Financial Efficiency
Gilead Sciences, Inc. posts a return on equity of -20.57 and a return on invested capital of 20.78.
| Return on Equity (ROE) | -20.57 |
| Return on Assets (ROA) | -6.17 |
| Return on Invested Capital (ROIC) | 20.78 |
| Return on Capital Employed (ROCE) | 40.57 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 3.29 |
Taxes
Over the trailing twelve months, Gilead Sciences, Inc. has paid 1.29B in income taxes, reflecting an effective tax rate of 37.84.
| Income Tax | 1.29B |
| Effective Tax Rate | 37.84 |
Stock Price Statistics
Gilead Sciences, Inc.'s stock has gained approximately 14.65043% over the past 52 weeks. The 50-day moving average sits at 28.84, while the 200-day moving average is 27.95.
| Beta (5Y) | N/A |
| 52-Week Price Change | 14.65043% |
| 50-Day Moving Average | 28.84 |
| 200-Day Moving Average | 27.95 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Gilead Sciences, Inc. generated 30.46B in revenue and converted that into -3.24B in net income, yielding earnings per share of -0.39. EBITDA reached 14.48B, while operating income came in at 11.72B.
| Revenue | 30.46B |
| Gross Profit | 24.24B |
| Operating Income | 11.72B |
| Pretax Income | -1.95B |
| Net Income | -3.24B |
| EBITDA | 14.48B |
| EBIT | 11.72B |
| Earnings Per Share (EPS) | -0.39 |
Balance Sheet
Gilead Sciences, Inc. holds 3.18B in cash and equivalents against 26.25B in total debt, resulting in a net debt position of 23.07B. Total book value stands at 11.83B, with working capital of 2.93B providing operational flexibility.
| Cash & Cash Equivalents | 3.18B |
| Total Debt | 26.25B |
| Net Debt | 23.07B |
| Equity (Book Value) | 11.83B |
| Book Value Per Share | 9.53 |
| Working Capital | 2.93B |
Cash Flow
Gilead Sciences, Inc. produced 13.55B in operating cash flow over the past twelve months. After subtracting -609.00M in capital expenditures, free cash flow totaled 12.94B - equivalent to 1.56 per share.
| Operating Cash Flow | 13.55B |
| Capital Expenditures | -609.00M |
| Free Cash Flow | 12.94B |
| FCF Per Share | 1.56 |
Margins
Gilead Sciences, Inc. operates with a gross margin of 79.59, reflecting its pricing power and cost economics. The operating margin of 38.47 and net profit margin of -10.64 provide insight into operational efficiency.
| Gross Margin | 79.59 |
| Operating Margin | 38.47 |
| Pretax Margin | -6.42 |
| Profit Margin | -10.64 |
| EBITDA Margin | 47.53 |
Dividends & Yields
The company's payout ratio of -125.56 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.49 |
| Dividend Yield | N/A |
| Payout Ratio | -125.56 |
| Shareholder Yield | 20.76 |
| FCF Yield | 9.43 |
Scores
Gilead Sciences, Inc. posts an Altman Z-Score of 3.16, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 3.16 |